Novel derivatives of 9-beta-D-arabinofuranosylpurines that are cytotoxic to variants of human leukemia lymphoblast cells resistant to both 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyladenine.
D001087:Arabinonucleosides / Q000633:toxicity*; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D003561:Cytarabine / Q000633:toxicity*; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007945:Leukemia, Lymphoid / Q000503:physiopathology*; D013329:Structure-Activity Relationship; D014740:Vidarabine / Q000633:toxicity*
D001087:Arabinonucleosides; D003561:Cytarabine; D014740:Vidarabine